Cel-Sci, Johns Hopkins Move Forward with LEAPS

Nov. 8.09 | About: Cel-Sci Corporation (CVM)

Shortly after the market open on Friday, Cel-Sci Corp. (NYSEMKT:CVM) issued a press release declaring that the company will commence a Clinical Study measuring the effectiveness of the company's LEAPS technology in the treatment of H1N1-hospitalized patients. According to the press release, blood will be drawn from the hospitalized patients and then the cells will be "activated" with the LEAPS-H1N1 treatment "in order to assess the cells' response as the basis for the planned future treatment of this patient population under a next-stage clinical trial protocol." [Quotes were taken directly from Friday's PR]

This study was expected, as the company informed investors in September that the FDA had given Cel Sci the 'go-ahead', but what is significant in my opinion, is the fact that Johns Hopkins has jumped on board. Johns Hopkins University is one of the nation's most prestigious - especially in terms of the School of Medicine. The fact that an "Institutional Review Board" of Johns Hopkins University gave the clearance for the this clinical study to proceed - with the Johns Hopkins name attached to it -should give sceptical investors a 'warm & fuzzy' that there is some significant potential for LEAPS to become an effective treatment for H1N1 patients.

In short, Johns Hopkins is no joke and the institution gives instant credibility to any ongoing clinical study that they are willing to attach their name to. Does that mean that LEAPS is now a sure bet? No, but the Scientists and Doctors at Hopkins saw something, and that makes VFC more confident than ever that there is more potential to the LEAPS-H1N1 treatment than many have been willing to speculate.

With the study now ready to start, news and updates could come quick; it'll be worth watching the wires over the next few weeks, in my opinion.

What also struck me as somewhat odd was the timing of the PR. Usually - at least in my own experiences - news that would be construed as positive is released towards the beginning of the week, not on Friday, so that the stock could build some early-week momentum rather than have the good news forgotten about by the time trading resumes on Monday.

This is purely speculation on my part, but the timing of the PR has me interested in the possibility that additional news releases may be forthcoming from Cel Sci in the near future.

On another note, I've been asked for a few to comment on some recent blog postings regarding Cel Sci on TheStreet.com website. I'll just say this: I've only read what has been copied and pasted from those blog posts onto other boards because I don't follow 'TheStreet.com', nor their blogs, but I've seen nothing pertinent regarding the potential of Cel Sci or its products come from 'TheStreet.' What I have seen are articles that, in my opinion, support an ulterior agenda and look to incite suspicion rather than discuss the potential of the products.

VFC doesn't play that game.

Additionally, regarding the whole Multikine licensing deal with Byron for South Africa, I didn't invest in Cel Sci in anticipation of South African royalties. Cel Sci has Teva (NYSE:TEVA) and Orient on board with Multikine and now Johns Hopkins on board with LEAPS H1N1 - all very established and well respected entities. As for Byron, it's a non issue, in my opinion. Someone has the rights to market Multikine in South Africa, and those rights could turn out to be very valuable if Multikine is deemed a success.

Things are just heating up for Cel Sci and a few games and distractions by the 'Big Boys' shouldn't deter investors from following the progression of the company.

The facts are these: The potential of LEAPS for H1N1 is real - Johns Hopkins just validated that fact - and Multikine is closer than ever to Phase III, judging by the progress being made at the Baltimore area manufacturing facility.

As always, this is just my opinion and each investor should do their own Due Diligence and then invest based on that DD and their own comfort level for risk.

'Nuff said, for now.

Disclosure: VFC is long CVM.